NR3C2 and obesity disorder: Prior work in a mouse model of obesity showed that treatment with a mineralocorticoid receptor antagonist, a drug with anti‐inflammatory effects in adipose tissue, reduced EAT SFA as measured by FAC MRI and increased perfusion reserve, which supports this hypothesis.20